KRAS and non-small cell lung carcinoma: In a retrospective analysis of a Chinese population of patients with KRAS-mutant advanced NSCLC, immunotherapy-based regimens achieved longer overall survival (OS) than chemotherapy-based regimens, which was independent of first or second-line setting, as well as of KRAS mutational subtypes10.